Home > Formulary : Paediatric > Recent Decisions > 2022 >
Decisions 14th June 2022
At the meeting on the 14th June, the following decisions were agreed
New Drug Requests
Approved
Insulin Fiasp (TLS Amber No Shared Care Protocol)
-
For type 1 diabetic patients with or without insulin pumps where postprandial hyperglycaemia is a particular problem
Other Formulary Decisions:
-
Dapsone tablets - for treatment of dermatoses and oral ulceration to be included on the BNSSG Paediatric Joint Formulary as TLS Amber 3 months once a shared care protocol has been developed and approved and there has been clarification of the monitoring requirements.
-
Dibotermin alfa (rhBMP-2) - for surgical treatment of congenital tibial psuedoarthorosis was not approved for inclusion onto the BNSSG Paediatric Formulary as it did not meet criteria for inclusion
-
Mirabegron – it was agreed to change the Traffic Light Status for mirabegron from TLS Red to TLS Amber 3 months on the BNSSG Paediatric Joint Formulary once a shared care protocol has been developed and approved.
-
Salbutamol tablets - to be removed from the Joint Formulary
- Nutrition and Blood Chapter Review and Update- Updates include: addition of information on ketogenic supplements, metabolic supplements, update of multivitamin preparation section, addition of L-ornithine, Creatine Monohydrate, Pyridoxal 5 phosphate, Biotin, Calcium folinate, hydroxocobalamin IM to metabolic section. Further applications may be expected to JFG for calcium/vitamin D supplements and Ketovite.